{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:54:06Z","timestamp":1790790846615,"version":"4.1.0"},"reference-count":33,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,5,2]]},"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Oncolytic virotherapy has become an important branch of cancer immunotherapy. This study investigated the efficacy of an oncolytic adenovirus (OAV), OncoViron, with synergistic mechanisms in the treatment of multiple solid tumors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>An OAV, OncoViron, was constructed and investigated by cytological experiments and implanted tumor models of multiple solid tumor cell lines to certify its anticancer efficacy, the synergistic effects of viral oncolysis and transgene anticancer activity of OncoViron, as well as oncolytic virotherapy combined with immunotherapy, were also verified.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The selective replication of OncoViron mediated high expression of anticancer factors, specifically targeted a variety of solid tumors and significantly inhibited cancer cell proliferation. On a variety of implanted solid tumor models in immunodeficient mice, immunocompetent mice, and humanized mice, OncoViron showed great anticancer effects on its own and in combination with programmed death 1 (PD-1) antibody and chimeric antigen receptor (CAR) T cells. Pathological examination, single-cell sequencing, and spatial transcriptome analysis of animal implanted tumor specimens confirmed that OncoViron significantly altered the gene expression profile of infected cancer cells, not only recruiting a large number of lymphocytes, natural killer cells, and mononuclear macrophages into tumor microenvironment (TME) and activated immune cells, especially T cells but also inducing M1 polarization of macrophages and promoting the release of more immune cytokines, thereby remodeling the TME for coordinating PD-1 antibody or CAR T therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The chimeric OncoViron is a novel broad-spectrum anticancer product with multiple mechanisms of synergistic and potentiated immunotherapy, creating a good opportunity for combined immunotherapy against solid tumors.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2022-004691","type":"journal-article","created":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T12:20:02Z","timestamp":1653394802000},"page":"e004691","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":18,"title":["Triple-serotype chimeric oncolytic adenovirus exerts multiple synergistic mechanisms against solid tumors"],"prefix":"10.1136","volume":"10","author":[{"given":"Yinghan","family":"Su","sequence":"first","affiliation":[{"name":"Department of General Surgery, Huashan Hospital, Cancer Metastasis Institute, Fudan University, Shanghai 200040, China"},{"name":"National Center for Liver Cancer (NCLC), Navy Military Medical University, Shanghai 201805, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Li","sequence":"additional","affiliation":[{"name":"National Center for Liver Cancer (NCLC), Navy Military Medical University, Shanghai 201805, China"},{"name":"Department of Molecular Oncology, Eastern Hepatobiliary Surgery Hospital, Navy Military Medical University, Shanghai 200438, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidan","family":"Ji","sequence":"additional","affiliation":[{"name":"National Center for Liver Cancer (NCLC), Navy Military Medical University, Shanghai 201805, China"},{"name":"Department of Molecular Oncology, Eastern Hepatobiliary Surgery Hospital, Navy Military Medical University, Shanghai 200438, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[{"name":"Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy & Cancer Institute, Xuzhou Medical University, Xuzhou 221002, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Fang","sequence":"additional","affiliation":[{"name":"Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy & Cancer Institute, Xuzhou Medical University, Xuzhou 221002, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Molecular Oncology, Eastern Hepatobiliary Surgery Hospital, Navy Military Medical University, Shanghai 200438, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Ang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Second People's Hospital of Hefei, Hefei 230011, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pathology, Second People's Hospital of Hefei, Hefei 230011, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Sen","sequence":"additional","affiliation":[{"name":"Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy & Cancer Institute, Xuzhou Medical University, Xuzhou 221002, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[{"name":"National Center for Liver Cancer (NCLC), Navy Military Medical University, Shanghai 201805, China"},{"name":"Department of Molecular Oncology, Eastern Hepatobiliary Surgery Hospital, Navy Military Medical University, Shanghai 200438, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junnian","family":"Zheng","sequence":"additional","affiliation":[{"name":"Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy & Cancer Institute, Xuzhou Medical University, Xuzhou 221002, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3396-7248","authenticated-orcid":false,"given":"Changqing","family":"Su","sequence":"additional","affiliation":[{"name":"National Center for Liver Cancer (NCLC), Navy Military Medical University, Shanghai 201805, China"},{"name":"Department of Molecular Oncology, Eastern Hepatobiliary Surgery Hospital, Navy Military Medical University, Shanghai 200438, China"},{"name":"Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy & Cancer Institute, Xuzhou Medical University, Xuzhou 221002, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lunxiu","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Huashan Hospital, Cancer Metastasis Institute, Fudan University, Shanghai 200040, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,5,24]]},"reference":[{"key":"2025100309310972000_10.5.e004691.1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13045-021-01075-5","article-title":"Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies","volume":"14","author":"Heidbuechel","year":"2021","journal-title":"J Hematol Oncol"},{"key":"2025100309310972000_10.5.e004691.2","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00043","article-title":"Melanoma unknown primary brain metastasis treatment with ECHO-7 oncolytic virus Rigvir: a case report","volume":"8","author":"Proboka","year":"2018","journal-title":"Front Oncol"},{"key":"2025100309310972000_10.5.e004691.3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/hum.2017.212","article-title":"Fighting cancer with viruses: oncolytic virus therapy in China","volume":"29","author":"Wei","year":"2018","journal-title":"Hum Gene Ther"},{"key":"2025100309310972000_10.5.e004691.4","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061383","article-title":"Talimogene Laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma","volume":"13","author":"Ferrucci","year":"2021","journal-title":"Cancers"},{"key":"2025100309310972000_10.5.e004691.5","doi-asserted-by":"crossref","DOI":"10.3390\/v13061158","article-title":"The current landscape of oncolytic herpes simplex viruses as novel therapies for brain malignancies","volume":"13","author":"Bernstock","year":"2021","journal-title":"Viruses"},{"key":"2025100309310972000_10.5.e004691.6","doi-asserted-by":"crossref","DOI":"10.4161\/21505594.2014.988098","article-title":"Oncolytic virus expressing RANTES and IL-15 enhances function of CAR-modified T cells in solid tumors","volume":"4","author":"Nishio","year":"2015","journal-title":"Oncoimmunology"},{"key":"2025100309310972000_10.5.e004691.7","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"2025100309310972000_10.5.e004691.8","doi-asserted-by":"publisher","DOI":"10.1038\/nm0697-639"},{"key":"2025100309310972000_10.5.e004691.9","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22020879","article-title":"Real-Time fluorescence image-guided oncolytic virotherapy for precise cancer treatment","volume":"22","author":"Yano","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025100309310972000_10.5.e004691.10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1059"},{"key":"2025100309310972000_10.5.e004691.11","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12040798","article-title":"External beam radiation therapy and Enadenotucirev: inhibition of the DDR and mechanisms of Radiation-Mediated virus increase","volume":"12","author":"Pokrovska","year":"2020","journal-title":"Cancers"},{"key":"2025100309310972000_10.5.e004691.12","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.3892\/ijo.2013.1812","article-title":"The effectiveness of the oncolytic activity induced by Ad5\/F35 adenoviral vector is dependent on the cumulative cellular conditions of survival and autophagy","volume":"42","author":"Kim","year":"2013","journal-title":"Int J Oncol"},{"key":"2025100309310972000_10.5.e004691.13","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1126\/science.abk3436","article-title":"Oncolytic virotherapy as immunotherapy","volume":"374","author":"Melcher","year":"2021","journal-title":"Science"},{"key":"2025100309310972000_10.5.e004691.14","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.omto.2021.01.015","article-title":"Efficient antitumor effects of a novel oncolytic adenovirus fully composed of species B adenovirus serotype 35","volume":"20","author":"Ono","year":"2021","journal-title":"Molecular Therapy - Oncolytics"},{"key":"2025100309310972000_10.5.e004691.15","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.220020"},{"key":"2025100309310972000_10.5.e004691.16","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.molonc.2011.10.001","article-title":"Inhibitory effect of survivin promoter-regulated oncolytic adenovirus carrying p53 gene against gallbladder cancer","volume":"5","author":"Liu","year":"2011","journal-title":"Mol Oncol"},{"key":"2025100309310972000_10.5.e004691.17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049693","article-title":"Oct4 positively regulates survivin expression to promote cancer cell proliferation and leads to poor prognosis in esophageal squamous cell carcinoma","volume":"7","author":"Li","year":"2012","journal-title":"PLoS One"},{"key":"2025100309310972000_10.5.e004691.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2012.10.007"},{"key":"2025100309310972000_10.5.e004691.19","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.canlet.2015.06.016","article-title":"Survivin in survival of hepatocellular carcinoma","volume":"379","author":"Su","year":"2016","journal-title":"Cancer Lett"},{"key":"2025100309310972000_10.5.e004691.20","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3892\/or.2012.2217","article-title":"The combination of an oxygen-dependent degradation domain-regulated adenovirus expressing the chemokine RANTES\/CCl5 and NK-92 cells exerts enhanced antitumor activity in hepatocellular carcinoma","volume":"29","author":"Li","year":"2013","journal-title":"Oncol Rep"},{"key":"2025100309310972000_10.5.e004691.21","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.M113.030254"},{"key":"2025100309310972000_10.5.e004691.22","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207384"},{"key":"2025100309310972000_10.5.e004691.23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00005-014-0273-2","article-title":"The anti-tumor activity of E1A and its implications in cancer therapy","volume":"62","author":"Chang","year":"2014","journal-title":"Arch Immunol Ther Exp"},{"key":"2025100309310972000_10.5.e004691.24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cbi.2009.06.002","article-title":"A truncated minimal-E1a gene with potency to support adenoviral replication mediates antitumor activity by down-regulating neu expression and preserving Rb function","volume":"181","author":"Fang","year":"2009","journal-title":"Chem Biol Interact"},{"key":"2025100309310972000_10.5.e004691.25","doi-asserted-by":"publisher","DOI":"10.1002\/1873-3468.13848"},{"key":"2025100309310972000_10.5.e004691.26","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2004.15.1229"},{"key":"2025100309310972000_10.5.e004691.27","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jconrel.2021.02.035","article-title":"Oncolytic adenovirus with hyaluronidase activity that evades neutralizing antibodies: VCN-11","volume":"332","author":"Mato-Berciano","year":"2021","journal-title":"Journal of Controlled Release"},{"key":"2025100309310972000_10.5.e004691.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.09.024"},{"key":"2025100309310972000_10.5.e004691.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.05.004"},{"key":"2025100309310972000_10.5.e004691.30","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.cytogfr.2020.10.007","article-title":"Cytokines in oncolytic virotherapy","volume":"56","author":"Pol","year":"2020","journal-title":"Cytokine Growth Factor Rev"},{"key":"2025100309310972000_10.5.e004691.31","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","article-title":"Nk cells stimulate recruitment of cdc1 into the tumor microenvironment promoting cancer immune control","volume":"172","author":"B\u00f6ttcher","year":"2018","journal-title":"Cell"},{"key":"2025100309310972000_10.5.e004691.32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.631713","article-title":"Harnessing the cDC1-NK cross-talk in the tumor microenvironment to battle cancer","volume":"11","author":"B\u00f6dder","year":"2021","journal-title":"Front Immunol"},{"key":"2025100309310972000_10.5.e004691.33","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000131","article-title":"CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency","volume":"8","author":"Li","year":"2020","journal-title":"J Immunother Cancer"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-004691","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T16:31:22Z","timestamp":1759509082000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-004691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5,24]]},"published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1136\/jitc-2022-004691"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-004691","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}